VEGF transcription and mRNA stability are altered by WT1 not DDS(R384W) expression in LNCaP cells

JENNIFER CASH, AMANDA KORCHNAK, JACQUELYN GORMAN, YASMEEN TANDON and GAIL FRAIZER

Department of Biological Sciences, Kent State University, Kent, OH 44242, USA

Received December 6, 2006; Accepted January 11, 2007

Abstract. To identify physiologically relevant WT1 transcriptional target genes in prostate cancer cells, we have established stably transfected LNCaP cell lines expressing either WT1(A), its mutant counterpart DDS(R384W), or vector control. Microarray analyses of these cells revealed that vascular endothelial growth factor (VEGF) was differentially expressed in the engineered lines. Regulation of VEGF by WT1 likely contributes to kidney angiogenesis during development and WT1 mutants such as DDS(R384W) are associated with the Denys-Drash syndrome (DDS), characterized by renal abnormalities. Recent mechanistic studies have demonstrated that the WT1(A) isoform binds VEGF promoter sequences and transcriptionally regulates VEGF reporter constructs. However, regulation of VEGF is complex, involving both transcriptional and post-transcriptional processes. This study examined the ability of hormone and Actinomycin D treatment to alter VEGF mRNA levels in stably transfected WT-LNCaP, DDS-LNCaP, or V-LNCaP prostate cancer cells. The rationale of this study was based on a previous finding that enhancement of VEGF expression in DDS-LNCaP cells occurred only in the presence of the androgen analog, R1881. One possible explanation for these results was that DDS-WT1 stabilized VEGF mRNA so that it accumulated to higher levels. This hypothesis was tested by treating engineered LNCaP cells with Actinomycin D (Act D) and then measuring VEGF mRNA levels by quantitative real-time PCR. The combined effects of WT1 or DDS(R384W) and hormone were tested in these message stability assays and also in transcription assays of transiently transfected LNCaP cells. The results indicated that DDS-WT1 is unable to regulate VEGF transcription or stabilize VEGF mRNA in LNCaP prostate cancer cells. However our observations are also consistent with wild-type WT1(A) having both transcriptional and post-transcriptional effects on VEGF mRNA levels in the presence of hormone.

These studies of VEGF regulation by WT1 and dysregulation by DDS(R384W) suggest an important role for WT1 in both normal and tumor-related angiogenesis.

Introduction

The Wilms’ tumor suppressor gene (WT1) encodes a multifunctional zinc-finger protein with many isoforms. The isoform WT1(A) lacking exon 5 and the KTS tripeptide is the transcriptionally active form that either represses or activates transcription, depending upon the gene target and cells tested (1). Mechanistic studies of WT1(A) focus on the role played by zinc fingers 2-4 (reviewed in refs. 2,3) and often compare the WT1(A) isoform to one of the naturally occurring zinc finger mutants associated with the Denys-Drash syndrome (DDS) (4), such as the common mutation DDS(R384W), resulting in an arg to trp substitution in the third zinc finger (2). In an effort to identify genes transcriptionally regulated by WT1 in prostate cancer cells, we have established stably transfected LNCaP cell lines expressing either WT1(A) WT-LNCaP, DDS-LNCaP, or V-LNCaP prostate cancer cells. Gene expression patterns of these three lines were compared using cDNA microarray analyses (6). Among those genes differentially expressed in the engineered lines was the angiogenesis gene, vascular endothelial growth factor (VEGF).

As a key mediator of angiogenesis, VEGF is tightly regulated at both the transcriptional and post-transcriptional levels. VEGF regulation is complex as it is up-regulated by hypoxia, growth factors, steroid hormones and transcription factors (7). To better understand the regulation of VEGF expression in these stably transfected prostate cancer cells, VEGF mRNA was quantified in hormone-treated cells using real-time quantitative RT-PCR. Surprisingly, VEGF expression was enhanced in LNCaP cells expressing the DDS(R384W) mutant, but only in the presence of the androgen analog, methyltrienolamine (R1881) (6). Based on the observations that VEGF levels were inversely related in the WT1- and DDS-LNCaP lines (relative to V-LNCaP), it was important to determine whether both WT1 and DDS(R384W) might regulate VEGF expression, and if so whether regulation by DDS(R384W) might differ from that mediated by wild-type WT1. Amongst its many functions, the WT1 zinc-finger protein can regulate expression by both DNA and RNA interactions (2,8). Interestingly, the predicted RNA binding domains are unaffected by the arg to trp mutation in the third

Correspondence to: Dr Gail Fraizer, Department of Biological Sciences, Kent State University, Kent, OH 44242, USA
E-mail: gfraizer@kent.edu

Key words: vascular endothelial growth factor, Wilms’ tumor gene, Denys-Drash syndrome, LNCaP, prostate cancer cells
zinc finger of DDS(R384W) and DDS WT1 retains the ability to bind RNA oligomers (9). Although WT1(A) binds the VEGF promoter and regulates its transcription (10), additional regulatory mechanisms could impact VEGF levels in LNCaP cells. Thus, our hypothesis was that elevated VEGF levels in hormone-treated DDS-LNCaP cells reflected stabilization of VEGF mRNA.

This hypothesis was consistent with the general belief that the DDS(R384W) mutant is transcriptionally dysfunctional (4) and with our observation that in the DDS-LNCaP cells, VEGF levels were only elevated when they were grown in the presence of the androgen analog, methyltrienolamine (R1881) (6). Since VEGF mRNA levels in DDS-LNCaP cells grown in charcoal stripped FCS in the absence of hormone were similar to those in V-LNCaP, we hypothesized that hormone and DDS together might enhance VEGF mRNA stability and thus increase levels detected by real-time RT-PCR. This hypothesis was tested by measuring VEGF mRNA levels in Actinomycin D (Act D)-treated WT-, DDS-, and V-LNCaP cells grown in the presence or absence of 5 nM R1881. VEGF mRNA levels were quantified using real-time quantitative PCR (QRT-PCR) and the effects of both Act D and hormone treatments were assessed in each cell line. In addition to message stabilization assays, transcriptional reporter assays were also performed in the presence and absence of hormone. The murine WT1 (A) expression construct and its mutant counterpart, DDS (R384W) (4) were transiently co-transfected, along with several VEGF promoter constructs, in LNCaP cells. Overall, the effects of WT1 and hormone treatment were tested on transcription (measured in transient transfection assays) and on message stability (measured in stably transfected LNCaP cells).

Materials and methods

**Hormone and Actinomycin treatment of cultured cells.** LNCaP prostate cancer cells were stably transfected as described previously (5), with the plasmids encoding the transcriptionally active isoform of WT1 (isoform A) or the DDS(R394W) mutant WT1 or pcDNA3.1, the vector. LNCaP cells (ATTC CRL 1740) and three of the engineered cell lines selected and characterized previously (5), were seeded into 6-well plates, and subconfluent monolayers were synchronized by serum starvation for 18 h prior to incubation in RPMI (BioWhittaker, MD) medium containing 10% fetal calf serum (FCS). For hormone induction studies RPMI medium was supplemented with 10% charcoal-dextran stripped fetal calf serum (Ch-FCS) and half of these cultures were also supplemented with 5 nM of the synthetic androgen, R1881 (methyltrienolone), because of its strong affinity for the androgen receptor (11). To measure mRNA stability, 2 h after release from serum-starvation cells were treated with either 0 or 5 μg/ml Act D. Initially, the effects of 2-h treatment with 5 μg/ml Act D was measured in LNCaP and V-LNCaP cells. Each experiment was performed in triplicate and repeated at least twice. Once the effect of Act D on VEGF levels was determined in V-LNCaP cells, then a time-course study was performed treating WT1-, DDS-, and V-LNCaP cells with Act D for 0, 0.5, 2, and 6 h prior to RNA isolation.

**RNA isolation, reverse transcription and quantitative real-time PCR.** RNA was isolated from subconfluent monolayers of cells in 6-well plates by the guanidium isothiocyanate method using the RNAqueous4PCR kit (Ambion, Austin TX) according to the manufacturer's protocol. The optional DNase treatment step was included after initial RNA isolation. The quality of the RNA was evaluated by electrophoresis on a 0.8% agarose-formaldehyde denaturing gel (12) and by optical density ratios at 260 and 280 nm. One μg of RNA from each sample was reverse transcribed at 37°C for 2 h using Superscript II (Invitrogen, Carlsbad, CA) and random hexamers (Perkin Elmer, Boston, MA) as described (5).

Quantitative real-time PCR was essentially performed as described (6) using the ABI 7000 and SYBR-Green PCR Master Mix (Applied Biosystems, Foster City, CA). Primer sequences are shown in Table I (F, forward; R, reverse) and amplification was performed using either 150 nM cyclophilin, (13), 150 nM β-actin (14) or 300 nM VEGF primers (13). The amplification conditions were 95°C for 10 min, 40 cycles at 95°C for 15 sec, 60°C for 1 min followed by the dissociation protocol beginning at 60°C. Quantitative analyses were performed as described (6), in accordance with the manufacturer's recommendations (Applied Biosystems). Relative quantitation of PCR amplified products was determined by

Table I. Forward and reverse primer sequences.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Primer sequences (5’-3’)</th>
<th>Amplicon (bp)</th>
</tr>
</thead>
</table>
| Cyclophilin<sup>b</sup> | F: CTC-CTT-TGA-GCT-CTG-AG  
R: CAC-CAC-ATG-CTT-GCC-ATC-C | 325 |
| VEGF<sup>b</sup> | F: CGA-AAC-CAT-GAA-CTT-GC  
R: CCT-CAG-TGG-GCA-CAC-ACG-CC | 302 |
| β-actin<sup>c</sup> | F: GTG-GGG-CGC-CCC-AGG-CA-CA  
R: GTC-CTT-AAATGC-AGC-GAT-TTC | 540 |

<sup>a</sup>Primers used for real-time RT-PCR amplification using SYBR-Green PCR Master Mix and an ABI 7000 (Applied Biosystems, Foster City, CA) as described in the text. <sup>b</sup>Sequence of human cyclophilin and VEGF gene primers as described (13). <sup>c</sup>Sequence of β-actin primers as described (14).
cells. Fold-differences were determined by the 2^\Delta\Delta CT\ method as previously described (15), as previously described (6).

**LNCaP cell transfections.** LNCaP prostate cancer cells were cultured in 12-well plates and transfected as described (16) using lipofectamine 2000 (Invitrogen) in serum- and antibiotic-free media. Hormone induction was performed as described above. The cytomegalovirus (CMV) promoter-driven pCMV-WT1(A) expression construct encoding the murine Wt1 gene (lacking both KTS insertion and exon 5) and the mutant DDS-WT1(R384W) expression plasmids were previously described (4,17,18). The pGL3-VEGF promoter-luciferase reporter constructs (VEGF 88, 411, 1012, 2274) were obtained from Dr K. Xie (19). All DNA was purified by the Qiagen plasmid Maxi kit (Qiagen, Carlsbad CA). All transfections were performed as described (16). Briefly, 0.25 ug of the stated VEGF promoter-luciferase reporter construct was co-transfected along with 5 ng of pRL-null, the promoterless-Renilla luciferase normalizer (Promega, Madison, WI), and increasing concentrations of the WT1(A) or DDS-WT1(R384W) expression constructs (0, 0.25, 0.5 μg). DNA levels were held constant by the addition of the empty CMV expression vector, pCMV4 (Promega). Six hours after DNA transfection, the medium was removed and replaced with fresh RPMI with 10% FCS. For hormone induction studies RPMI medium contained 10% charcoal-dextran stripped fetal calf serum (Ch-FCS) and half of the cultures were cultured in 10% ChS-FCS without R1881. Then 5 ug/ml Act D was added to half of each of these cultures (with or without R1881) to determine whether hormone treatment was inducing VEGF transcription or simply stabilizing message levels. After 2 h of Act D treatment (or 4 h total) cells were harvested and mRNA levels were not increased by hormone treatment of cells cultured without R1881 (Table II). However, VEGF induced a 2-fold increase in VEGF mRNA levels, relative to cells cultured without R1881. 1 Serum-starved cells were cultured in the presence of 10% CHS-FCS with or without 5 nM R1881 for 2 h followed by 2 h of treatment with or without 5 μg/ml Act D. Fold-increase values were determined as described above. VEGF expression was normalized relative to controls cyclophilin or β-actin.

### Results and discussion

**Actinomycin D treatment prevented hormone-induced VEGF expression in LNCaP and V-LNCaP control cells.** To confirm that treatment with R1881 induced VEGF expression, LNCaP cells were serum-starved overnight and then half of the cultures were treated for 2 h with 5 nM R1881 (and half were cultured in 10% CHS-FCS without R1881). Then 5 μg/ml Act D was added to half of each of these cultures (with or without R1881) to determine whether hormone treatment was inducing VEGF transcription or simply stabilizing message levels. After 2 h of Act D treatment (or 4 h total) cells were harvested, RNA isolated and VEGF levels measured by quantitative real-time PCR analysis (QRT-PCR). RNA levels were normalized using two methods; by comparison with cyclophilin or β-actin expression, using the 2^\Delta\Delta CT\ method to compare hormone-treated with untreated cells. Four hours of hormone treatment induced a 2-fold increase in VEGF mRNA levels, relative to cells cultured without R1881 (Table II). However, VEGF mRNA levels were not increased by hormone treatment of cells also treated with 5 μg of Act D, as VEGF mRNA remained at levels equivalent to those in cells cultured in 10% CHFCS without R1881. These results indicated that hormone enhanced transcription was not Act D resistant (and therefore represented newly transcribed mRNA), suggesting that hormone affected transcription, but not message stability.

Before analyzing the effect of WT1 expression on VEGF transcript levels, control LNCaP cells stably transfected with the empty vector (V-LNCaP) were tested and also found to be hormone responsive and Act D sensitive (Table III). As described above for Table II, serum-starved cells were cultured for 2 h in the presence or absence of 5 nM R1881, followed by culturing in the presence or absence of 5 μg/ml Act D. VEGF
mRNA levels were measured by QRT-PCR and values were normalized by both cyclophilin or ß-actin, using the 2^-ddCt method (15) to compare Act D-treated with untreated cells. The effect of Act D on V-LNCaP cells was similar to that on untransfected LNCaP cells, in that VEGF levels were 2-fold lower relative to cells cultured for 2 h without R1881 (Table III). The presence of hormone did not prevent the reduction of VEGF mRNA levels by Act D treatment of V-LNCaP cells, suggesting increased message stability did not account for the previously observed hormone-mediated elevation of VEGF levels in V-LNCaP cells (6). Indeed the relative reduction of VEGF levels was greater in the presence of hormone, since in the absence of Act D, R1881 increased VEGF levels (Table III).

Actinomycin D reduced VEGF levels in LNCaP cells engineered to express mutant DDS-WT1. Having demonstrated that 2 h of Act D treatment reduced VEGF mRNA levels two-fold in LNCaP and V-LNCaP cells, it was important to determine whether expression of WT1 or DDS-WT1 in stably transfected LNCaP cells would alter the response to Act D. If the previously observed elevated levels of VEGF in DDS-LNCaP cells (6) were due to mRNA stabilization, as hypothesized, then Act D treatment should have little effect. VEGF mRNA levels were measured first in cells cultured without R1881, to establish a baseline (Fig. 1A), then in cells treated with 5 nM R1881 (Fig. 1B). As expected, Act D treatment reduced VEGF levels two-fold in cells cultured without R1881 (Fig. 1A). In fact, VEGF mRNA levels in DDS-LNCaP cells paralleled those in V-LNCaP, suggesting that in the absence of hormone, expression of DDS-LNCaP had no significant effect on message stability. This was consistent with previous results showing that VEGF levels increased in DDS-LNCaP cells only when hormone treated (6). Surprisingly, when DDS-LNCaP and Va LNCaP cells were cultured in media containing 5nM R1881, mRNA levels also declined 2-fold (Fig. 1B). Thus, the presence of the DDS-WT1 protein appeared insufficient to stabilize VEGF mRNA in either the presence or absence of R1881. Interestingly, expression of the wild-type WT1 in the absence of R1881 may have slowed the decline in VEGF mRNA levels (Fig. 1A), reaching VEGF levels of the control V-LNCaP cells by 2 h. Additionally, WT1 appeared to transiently stabilize VEGF mRNA levels in R1881-treated cells, as message levels were elevated 2-fold at the 0.5-h time point and did not decline below baseline, even after 2-h treatment (Fig. 1B). This modest stabilization appeared to be hormone enhanced, as VEGF mRNA levels declined 1.5-fold after 2 h in the absence of hormone.

### Table III. Actinomycin D treatment decreased VEGF mRNA levels in V-LNCaP cells treated with 5 nM R1881.

<table>
<thead>
<tr>
<th>Act D effect</th>
<th>(Relative to 0 μg Act D)^a</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0 nM R1881b</td>
</tr>
<tr>
<td>Normalized cyclophilin^c</td>
<td>2.22x Down</td>
</tr>
<tr>
<td>Normalized ß-actin^c</td>
<td>2.13x Down</td>
</tr>
</tbody>
</table>

^aCells were treated with 0 or 5 μg/ml Act D following release from serum starvation, as described in the text. RNA levels were measured by real-time quantitative RT-PCR and relative quantitation of PCR amplified products was determined by 2^-ddCt analysis (15) as described in the text. Fold-decrease values are shown relative to cells cultured without Act D. ^bSerum-starved cells were cultured in the presence of 10% CHS-FCS with 5 nM R1881 for 2 h followed by 2 h of treatment with 0 or 5 μg/ml Act D. Fold-decrease values were determined as described above. ^cVEGF expression was normalized relative to controls cyclophilin or ß-actin.
R1881 treatment does not alter DDS-WT1 inactivity

Figure 3. DDS-WT1(R384W) did not activate the full-length VEGF promoter. VEGF 2274, even with hormone R1881 treatment. LNCaP cells were co-transfected with the full-length VEGF promoter, VEGF 2274, and increasing amounts of DDS-WT1(R384W): 0 ng (black), 250 ng (white), or 500 ng (grey). DNA levels were held constant as described in Fig. 2. Cells were cultured in RPMI-10% ChS-FCS after co-transfection and treated with either 0 or 5 nM R1881 for 72 h prior to harvesting. The luciferase values were normalized as described in the text and are shown ± SEM. Each experiment was performed in triplicate and repeated three times. Transfection of DDS-WT1(R384W) had no significant effect, as determined by ANOVA.

Figure 2. VEGF promoter was activated by transfection of murine WT1(A) but not by DDS-WT1(R384W) mutant. (A) VEGF promoter has multiple WT1 binding sites. Proximal promoter region has both WT1 and EGR-1 sites to which WT1 could potentially bind. Two sites have been verified to bind WT1 protein, one in the VEGF 88 region and one in the 5’ region of the VEGF 411 construct (adapted from ref. 10, not drawn to scale). (B) DDS-WT1(R384W) is not transcriptionally active in LNCaP cells. Wild-type WT1 or DDS-WT1(R384W) mutant or empty control vector was co-transfected along with a given VEGF-luciferase reporter construct (V88, V411, or V1012) in LNCaP cells. Cells were co-transfected with increasing amounts of WT1: 0 ng (black), 250 ng (white), or 500 ng (grey); or 500 ng of DDS-WT1(R384W) (striped). DNA levels were held constant by transfecting pCMV4 empty vector control DNA. Each experiment was performed in triplicate and repeated three times. Luciferase activity was normalized as described in the text and is shown ± SEM. Significance was determined by ANOVA (p<0.005, **p<0.001, ***p<0.0001).

R1881 (Fig. 1A). Taken together, these results suggest that DDS-WT1 is unable to stabilize VEGF mRNA whether in the presence or absence of hormone, but hormone transiently enhanced VEGF stability in those cells expressing WT1. Thus, a functional zinc finger domain might enhance VEGF message stability in the presence of hormone.

**DDS-WT1 did not regulate VEGF transcription.** Given that elevated VEGF mRNA levels could not be explained by message stabilization in hormone-treated DDS-LNCaP cells, it was important to determine whether the DDS-WT1 mutant had some residual transcriptional activity that could account for increased transcription initiation. Thus, reporter assays were performed in LNCaP cells transiently transfected with the DDS-WT1(R384W) mutant and several VEGF promoter constructs (Fig. 2A). Previous results demonstrated that the proximal VEGF promoter region (contained within the VEGF 88 and VEGF 411 constructs) was transcriptionally activated by WT1 and two functional DNA binding sites were located within this proximal promoter region (10). The aim here, was to determine the importance of the zinc finger DNA binding domain in regulating transcription of the proximal promoter region, since the DDS-WT1 (R384W) mutant has an altered DNA binding domain and was not expected to bind DNA (4). The WT1 mutant DDS-WT1(R384W) expression construct was derived from a murine WT1 gene, and so was compared to the wild-type murine WT1(A) expression construct. A similar up-regulation of the proximal VEGF promoter constructs, VEGF 88 and VEGF 411, was observed when the murine WT1 was transfected into LNCaP cells (Fig. 2B). WT1 (500 ng) increased the activity of VEGF-88 and VEGF-411 4.3- and 4.9-fold, respectively, in LNCaP cells. WT1 also increased the activity, though to a lesser extent, of the larger VEGF promoter construct that included the more distal regions, VEGF-1012 (2.5-fold). Activation of these VEGF promoter constructs was considered significant as determined by ANOVA (p<0.0024, p<0.0001 and p<0.0001, for VEGF-88, -411, and -1012, respectively). Since the murine WT1 gene behaved similarly to the human gene in LNCaP cells, this strengthened the conclusion that the lack of activation of VEGF reporter constructs by DDS-WT1 was due to the zinc finger mutation. The inactivity of the DDS-WT1(R384W) construct was confirmed in two other cell lines, HEK-293 kidney cells and PC3 prostate cancer cells, as well (data not shown). Overall, this suggested that the DNA binding domain of WT1 plays an essential role in the transcriptional regulation of VEGF.

While no dimeric androgen receptor binding site has been identified in the VEGF promoter, we and others have observed that the VEGF promoter is androgen responsive (10,21-23).
Since R1881 increases the transcriptional activation of the VEGF promoter by wild-type WT1 (10), it was important to determine whether hormone could also enhance activation by DDS-WT1. Therefore, the combined effects of 5 nM R1881 and increasing amounts of DDS-WT1 were tested on the full-length VEGF promoter containing several hormone responsive vitamin D, estrogen, and ER-α/SP1 composite sites (24,25). Transiently transfected DDS-WT1 failed to activate the full-length VEGF promoter, whether cells were treated with R1881 or left untreated (Fig. 3). In contrast to our previous studies showing hormone-enhanced WT1 activity (10,16), R1881 did not enhance the activity of DDS-WT1.

Importance of VEGF regulation by WT1 and DDS-WT1. Overall, these results indicated that DDS-WT1 was unable to regulate the transcription of the VEGF promoter, or stabilize VEGF mRNA transcripts. If such inactivity occurred during development, it could potentially contribute to angiogenesis defects. Recent studies of angiogenesis in murine kidney cultures demonstrate that WT1 stimulates growth and nephrogenesis by inducing vegfa in metanephric mesenchyme (26). WT1 is essential for kidney development (27-29) and is co-expressed with VEGF in normal kidney cells and in some Wilms' tumors (26,29-31). In contrast, expression of the DDS-WT1 mutant is associated with the DDS syndrome, characterized by kidney malformations (along with renal mesangial sclerosis, genital anomalies and elevated risk of Wilms' tumor) (4). For both developmental and cancer studies it is important to elucidate the mechanisms whereby WT1 regulates VEGF and thereby, angiogenesis. Taken together, all of these studies suggest that VEGF is a physiologically relevant target of WT1 regulation in several different tissues, including prostate. Prostate VEGF expression is elevated in prostate cancer cells (32) and WT1 mRNA has been observed in some cultured prostate cancer cells and tissue samples (17,33,34) (Brown K, and Fraizer G, unpublished data). The finding that WT1 can regulate VEGF in prostate cancer cells (10) is consistent with its ability to regulate several other prostate cancer growth control pathways (17,18,35-41), including the IGF axis. In fact, many of the growth factors that affect VEGF levels are themselves regulated by WT1 (35,36,42-45). Interestingly, the insulin-like growth factor I receptor (IGF-1R) has also been reported to respond to DDS-WT1 co-transfection (46). One possibility is that DDS-WT1 could indirectly affect VEGF expression by regulating IGF-1R expression. This potential activity retained by DDS-WT1 might explain why VEGF levels were increased in the stably transfected DDS-LNCaP cells (6), although no transcriptional activity was detected in the transient transfection assays.

Although the different functions of the WT1 zinc-finger isoforms are still being identified, it is clear that WT1 can regulate expression by both DNA and RNA interactions (2,8). Indeed, both the WT1 (-KTS) isoform and the WT1-DDS mutant bind RNA oligomers (9,47,48). Since the 3'UTR of VEGF transcript has a C-rich region that binds RNA stabilizing proteins (49,50) and binding of RNA stabilizing proteins is androgen responsive, it seemed reasonable that DDS might enhance R1881-mediated stabilization of VEGF mRNA. Surprisingly our observations are consistent with wild-type WT1, but not DDS-WT1, enhancing mRNA stability.

Acknowledgments

We gratefully acknowledge receipt of the VEGF luciferase constructs from Dr K. Xie and the DDS-WT1 constructs from Dr J. Pelletier. These studies were supported by the NIH (R15CA113360) and the Kent State University Research Council.

References


